Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 4Neoplasm Metastasis 2Carcinoma, Intraductal, Noninfiltrating 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1

Interventions

abemaciclib 2Radiotherapy 2sargramostim 1ribociclib 1palbociclib 1niraparib 1exemestane 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Growth and Development 1Fulvestrant 1Everolimus 1Cyclophosphamide 1Continuous Positive Airway Pressure 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unilateral Breast Neoplasms × Colony-Stimulating Factors × Breast × Clear all
NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Academic and Community Cancer Research United

Phase 2 Active not recruiting
280 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡